Patents by Inventor François-Xavier Le Gros
François-Xavier Le Gros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10350286Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: GrantFiled: February 16, 2017Date of Patent: July 16, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
-
Patent number: 9913896Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.Type: GrantFiled: December 14, 2016Date of Patent: March 13, 2018Assignee: MERIAL, INC.Inventor: Francois Xavier Le Gros
-
Publication number: 20170224807Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: ApplicationFiled: February 16, 2017Publication date: August 10, 2017Applicant: Merial Inc.Inventors: Michel Bublot, Frederic REYNARD, François-Xavier LE GROS
-
Publication number: 20170173146Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.Type: ApplicationFiled: December 14, 2016Publication date: June 22, 2017Applicant: Merial, Inc.Inventor: Francois Xavier LE GROS
-
Patent number: 9616118Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: GrantFiled: May 2, 2014Date of Patent: April 11, 2017Assignee: MERIAL, INC.Inventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
-
Patent number: 9555098Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.Type: GrantFiled: September 10, 2013Date of Patent: January 31, 2017Assignee: MERIAL INC.Inventor: Francois Xavier Le Gros
-
Publication number: 20150216964Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.Type: ApplicationFiled: September 10, 2013Publication date: August 6, 2015Applicant: Merial, Inc.Inventor: Francois Xavier Le Gros
-
Patent number: 8871220Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: GrantFiled: April 2, 2010Date of Patent: October 28, 2014Assignee: Merial LimitedInventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
-
Publication number: 20140234358Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: ApplicationFiled: May 2, 2014Publication date: August 21, 2014Applicant: MERIAL LIMITEDInventors: Michel Bublot, Frederic REYNARD, François-Xavier LE GROS
-
Patent number: 8329163Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.Type: GrantFiled: April 20, 2011Date of Patent: December 11, 2012Assignee: Merial LimitedInventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois Xavier Le Gros
-
Publication number: 20120009218Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.Type: ApplicationFiled: April 20, 2011Publication date: January 12, 2012Applicant: Merial LimitedInventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
-
Patent number: 8062645Abstract: The present invention relates to the field of vaccination against Salmonella in animals, particularly avian animals. The present invention also encompasses kits and uses of Salmonella immunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle and at least one attenuated Salmonella, administered to an avian animal before at least one boost-administration of an inactivated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle, and at least one inactivated Salmonella.Type: GrantFiled: December 10, 2007Date of Patent: November 22, 2011Assignee: Merial LimitedInventors: François-Xavier Le Gros, Stephane Lemiere
-
Publication number: 20110212129Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.Type: ApplicationFiled: December 7, 2010Publication date: September 1, 2011Applicants: SANOFI PASTEUR S.A., MERIAL LIMITEDInventors: Catherine Gerdil, Catherine Moste, Isabelle Legastelois, Michel Marie Joseph Bublot, François-Xavier Le Gros
-
Patent number: 7943125Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.Type: GrantFiled: October 7, 2008Date of Patent: May 17, 2011Assignee: Merial LimitedInventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
-
Patent number: 7871807Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.Type: GrantFiled: September 26, 2008Date of Patent: January 18, 2011Assignee: Sanofi Pasteur, S.A.Inventors: Catherine Gerdil, Catherine Moste, Isabelle Legastelois, Michel Joseph Marie Bublot, Francois-Xavier Le Gros
-
Publication number: 20100255029Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: ApplicationFiled: April 2, 2010Publication date: October 7, 2010Inventors: MICHEL BUBLOT, FRANÇOIS-XAVIER LE GROS, FREDERIC REYNARD
-
Publication number: 20090252766Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.Type: ApplicationFiled: October 7, 2008Publication date: October 8, 2009Inventors: Helen Rachel CROOKE, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
-
Publication number: 20090081255Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.Type: ApplicationFiled: September 26, 2008Publication date: March 26, 2009Applicant: SANOFI PASTEURInventors: Michel Marie Joseph Bublot, Francois-Xavier Le Gros, Catherine Gerdil, Catherine Moste, Isabelle Legastelois
-
Patent number: 7449178Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.Type: GrantFiled: April 3, 2003Date of Patent: November 11, 2008Assignee: Merial LimitedInventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
-
Publication number: 20080220022Abstract: The present invention relates to the field of vaccination against Salmonella in animals, particularly avian animals. The present invention also encompasses kits and uses of Salmonella immunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle and at least one attenuated Salmonella, administered to an avian animal before at least one boost-administration of an inactivated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle, and at least one inactivated Salmonella.Type: ApplicationFiled: December 10, 2007Publication date: September 11, 2008Inventors: Francois-Xavier Le Gros, Stephane Lemiere